Reversal caused by n-butylidenephthalide from the deficits of inhibitory avoidance performance in rats.
The present study was designed to investigate the mechanism of action of n-butylidenephthalide on the deficits of inhibitory avoidance performance induced by drugs in rats with piracetam as a positive control. n-Butylidenephthalide attenuated the scopolamine-induced and mecamylamine-induced acquisition impairment, and also attenuated the acquisition impairment induced by scopolamine plus mecamylamine. Furthermore, scopolamine methylbromide, a peripheral cholinergic muscarinic receptor antagonist, did not block the counteracting effect of n-butylidenephthalide on the scopolamine-induced acquisition impairment. n-Butylidenephthalide attenuated the impairment of inhibitory avoidance performance induced by the central acetylcholinergic neurotoxin AF64A administered intracisternally. From the above results, we suggest that n-butylidenephthalide attenuated the deficits of inhibitory avoidance performance induced by drugs, which are the effects related to activating the central but not the peripheral cholinergic neuronal system via muscarinic and nicotinic receptors.
Institute of Chinese Pharmaceutical Sciences, China Medical College, Taichung, Taiwan, ROC. rei106@tcts1.seed.net.tw
M T
MT
Hsieh
C R
CR
Wu
L W
LW
Lin
C C
CC
Hsieh
C H
CH
Tsai
D000818:Animals; D001362:Avoidance Learning / Q000187:drug effects*; D018680:Cholinergic Antagonists / Q000494:pharmacology; D008297:Male; D008464:Mecamylamine / Q000494:pharmacology; D010796:Phthalic Anhydrides / Q000494:pharmacology*; D010889:Piracetam / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012601:Scopolamine / Q000494:pharmacology
D018680:Cholinergic Antagonists; D010796:Phthalic Anhydrides; D008464:Mecamylamine; D012601:Scopolamine; C026105:butylidenephthalide; D010889:Piracetam